CHICAGO / Sep 20, 2023 / Business Wire / GE HealthCare (Nasdaq: GEHC) today released its inaugural Sustainability Report, which describes the steps the Company has taken to establish its stand-alone environmental, social, and governance (ESG) practice and infrastructure, as well as how it has bolstered the foundation put in place prior to its spin-off from GE. The report incorporates findings from GE HealthCare’s existing ESG materiality assessment, which informed the Company’s ESG strategy, and outlines the Company’s long-term ESG objectives and progress against previous goals.
“With a solid foundation from our legacy as part of GE and our journey as a new independent company, we are redefining our focus on sustainability by building on our historical strengths and developing new capabilities for the future,” said GE HealthCare President and CEO Peter J. Arduini. “ESG responsibility is central to our vision and we are embedding these principles into the core of our business and risk management as we seek to create a world where healthcare has no limits.”
Through an ESG materiality assessment conducted prior to the company’s spin-off, GE HealthCare has defined a list of focus areas deemed as the most relevant by stakeholders for its sustainability strategy. These five focus areas include the following and are underpinned by the Company's longstanding commitments to innovation, product quality, and integrity:
GE HealthCare recognizes sustainability must be a Company priority. The Board oversees management’s establishment and execution of corporate strategy, along with the company’s ESG program and activities, and there is a cross-functional Enterprise Stewardship Program (ESP) that encompasses both ESG and Enterprise Risk Management. GE HealthCare appointed Kelvin Sanborn as the company’s ESG Program Lead who brings deep sustainability experience, having previously led GE HealthCare's Global Environment Team.
Highlights from the Company’s inaugural Sustainability Report include:
Environmental Impact
Social Impact
Governance and Accountability
“GE HealthCare recognizes the global significance of fulfilling our purpose and delivering on our objectives and is pleased to have reduced our operational GHG emissions by 27% versus our 2019 baseline,” shared Kelvin Sanborn, ESG Program Leader, GE HealthCare. “With our broader ESG strategy and priorities in mind, we are carrying out a climate risk assessment that will inform our climate transition plan, as well as developing a net zero roadmap for Scope 1, 2, and 3 GHG emissions, with targets expected to be submitted for validation to the Science Based Targets initiative by year-end.”
GE HealthCare intends to issue an updated Task Force on Climate-Related Financial Disclosures (TCFD) report following the completion of the climate risk assessment. The Company also plans to refresh its materiality assessment in 2024. Additionally, GE HealthCare plans to expand the Reporting Standards used for disclosing its ESG information and is currently looking into how its goals align with the UN SDGs.
Learn more about GE HealthCare’s 2022 Sustainability Report.
Forward-looking Statements
This release contains forward-looking statements. These forward-looking statements might be identified by words, and variations of words, such as “will,” “expect,” “may,” “would,” “could,” “plan,” “believe,” “anticipate,” “intend,” “estimate,” “potential,” “target,” “goal,” and similar expressions. These forward-looking statements may include, but are not limited to, statements about the Company’s business and ESG plans, performance, and goals, including environmental targets and plans related to the Company’s social impact and cybersecurity and data privacy. These forward-looking statements may be based on standards for measuring progress that are still developing, internal controls and processes that continue to evolve, and assumptions that are subject to change in the future. These statements are not guarantees of future performance, nor promises that goals or targets will be met, and are subject to numerous and evolving risks and uncertainties that the Company may not be able to predict or assess. Please see the “Risk Factors” section of the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission and any updates or amendments it makes in future filings. There may be other factors not presently known to the Company or which it currently considers to be immaterial that could cause the Company’s actual results to differ materially from those projected in any forward-looking statements the Company makes. The Company does not undertake any obligation to update or revise its forward-looking statements except as required by applicable law or regulation.
About GE HealthCare Technologies Inc.
GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 100 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are an $18.3 billion business with 50,000 employees working to create a world where healthcare has no limits.
Follow us on Facebook, LinkedIn, Twitter, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com/ for more information.
Last Trade: | US$77.09 |
Daily Change: | -2.16 -2.73 |
Daily Volume: | 3,055,620 |
Market Cap: | US$35.220B |
December 05, 2024 December 03, 2024 December 01, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB